Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds
Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy.
Johnson & Johnson (JNJ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 8,708,762 | $1,444,261,119 | +7% | 0.63% |
| 2. | AQR Capital Management Cliff Asness | 5,265,710 | $873,265,458 | +52% | 0.9% |
| 3. | 5,001,500 | $829,448,760 | +32% | 0.16% | |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,301,356 | $547,496,879 | +40% | 0.44% |
| 5. | 2,607,600 | $432,444,384 | +47% | 0.08% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $145.53 | 100 | $14,553.00 | 250 | 2024-04-30 | Filing | |
| $147.22 | 1,000 | $147,220.00 | 1,000 | 2024-12-12 | Filing | |
| $127.69 | 500 | $63,843.00 | 16,030 | 2020-03-13 | Filing | |
| $141.28 | 5,000 | $706,399.00 | 5,000 | 2019-12-13 | Filing | |
| $139.68 | 3,000 | $419,040.00 | 3,000 | 2019-06-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.88 | 6,999 | $1,160,994.12 | 21,001 | 2025-02-25 | Filing | |
| $156.15 | 403 | $62,928.45 | 15,098 | 2025-02-18 | Filing | |
| $153.89 | 13,015 | $2,002,878.35 | 0 | 2025-02-07 | Filing | |
| $165.06 | 5,635 | $930,113.10 | 18,973 | 2024-08-30 | Filing | |
| $162.16 | 8,891 | $1,441,764.56 | 15,043 | 2024-03-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 257,868 | $39,301,662 | 2.8% | |
| 2. | 100,693 | $15,380,856 | 0.51% | |
| 3. | 69,350 | $10,593,262 | 2.19% | |
| 4. | 46,599 | $7,118,014 | 1.76% | |
| 5. | 40,498 | $6,186,059 | 0.55% |
News See All
10 Best Dip Stocks to Buy According to Billionaires
On July 3rd, Dan Ives, Global Head of Tech Research at Wedbush, joined CNBC to discuss the technology sector.
15 Set-It-and-Forget-It Stocks to Buy According to Analysts
As expectations for trade agreements and potential rate cuts reduced investor anxiety, the S&P 500 and Nasdaq reached record closing highs on June 30, concluding their strongest quarter in over a year...
Johnson & Johnson’s (JNJ) IMAAVY Demonstrates Superior gMG Control
Johnson & Johnson (NYSE:JNJ) is one of the 12 stocks that will make you rich in 10 years. On June 23, J&J announced new data from an indirect treatment comparison (ITC) study.
12 Stocks That Will Make You Rich in 10 Years
One of the most read (and recommended) books on investing is Benjamin Graham’s The Intelligent Investor. Among many others, long-term investing is a foundational theme in the book.
Why JNJ Is a Long-Term Winner
Johnson & Johnson (NYSE:JNJ) is a long-established leader in the healthcare industry, with a strong portfolio of high-performing drugs in areas like immunology and cancer treatment, along with a thriving...
Johnson & Johnson CAR T Therapy Shows 80% Response in Lymphoma Trial
Johnson & Johnson (NYSE:JNJ) ranks among the top stocks for an early retirement portfolio.
Johnson & Johnson (JNJ) Launches Two New Plating Systems in the US
Johnson & Johnson (NYSE:JNJ) is one of the 10 Best and Cheap Stocks to Buy Now.
Johnson & Johnson MedTech Expands VOLT Platform With New Wrist, Upper Arm Fracture Systems
Johnson & Johnson (NYSE:JNJ) is one of the best Fortune 500 stocks to buy according to billionaires.
10 Best Wide Moat Dividend Stocks to Invest in
Wide-moat stocks refer to companies that possess lasting competitive strengths, helping them stay ahead of rivals.
Billionaire Hedge Funds
